Trilogy International Partners Inc., together with its subsidiaries, provides wireless voice and data communications services to customers and international visitors roaming on its networks in the United States, Bolivia, and New Zealand. Its wireless voice and data communications services include local, international long distance, and roaming services. The Company also provides fixed broadband communications services to business and residential customers. It serves approximately 15.4 million customers. The company is headquartered in Bellevue, Washington.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Phone+1-425-4585900
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesC$791.59 million
Profitability
Miscellaneous
Employees1,883
OptionableNot Optionable
Trilogy International Partners (TSE:TRL) Frequently Asked Questions
What is Trilogy International Partners' stock symbol?
Trilogy International Partners trades on the Toronto Stock Exchange (TSX) under the ticker symbol "TRL."
How often does Trilogy International Partners pay dividends? What is the dividend yield for Trilogy International Partners?
Trilogy International Partners declared a quarterly dividend on Friday, April 13th. Investors of record on Friday, May 4th will be given a dividend of 0.02 per share on Friday, May 4th. This represents a $0.08 annualized dividend and a dividend yield of 3.17%. The ex-dividend date of this dividend is Friday, April 13th. View Trilogy International Partners' Dividend History.
When is Trilogy International Partners' next earnings date?
What price target have analysts set for TRL?
3 analysts have issued twelve-month price objectives for Trilogy International Partners' shares. Their forecasts range from C$3.00 to C$8.00. On average, they expect Trilogy International Partners' stock price to reach C$4.67 in the next year. This suggests a possible upside of 85.2% from the stock's current price. View Analyst Price Targets for Trilogy International Partners.
What is the consensus analysts' recommendation for Trilogy International Partners?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trilogy International Partners in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Trilogy International Partners.
Has Trilogy International Partners been receiving favorable news coverage?
Media stories about TRL stock have trended somewhat positive on Sunday, according to InfoTrie. InfoTrie scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Trilogy International Partners earned a news impact score of 1.4 on InfoTrie's scale. They also assigned media coverage about the specialty pharmaceutical company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Trilogy International Partners' key competitors?
Some companies that are related to Trilogy International Partners include Pharmaxis (PXS), NanoViricides (NNVC), Patrys (PAB), Avivagen (VIV), Antisense Therapeutics (ANP), China Pharma (CPHI), Allergy Therapeutics (AGY), Bayer (BAYN), Bayer (BAYN), BEXIMCO PHARMAC/S GDR REGS (BXP), Cathay International (CTI), Dechra Pharmaceuticals (DPH), Eco Animal Health Group (EAH), Futura Medical (FUM) and Hutchison China MediTech (HCM).
Who are Trilogy International Partners' key executives?
Trilogy International Partners' management team includes the folowing people:
- Mr. John William Stanton, Co-Founder, Chairman & Lead Director (Age 64)
- Mr. Bradley Jay Horwitz, Co-Founder, Pres, CEO & Non-Independent Director (Age 63)
- Ms. Theresa E. Gillespie, Co-Founder & Non-Independent Director (Age 66)
- Mr. Erik Mickels, Sr. VP & CFO
- Mr. Scott Morris, Sr. VP, Gen. Counsel & Corp. Sec.
How do I buy shares of Trilogy International Partners?
Shares of TRL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Trilogy International Partners' stock price today?
One share of TRL stock can currently be purchased for approximately C$2.52.
How big of a company is Trilogy International Partners?
Trilogy International Partners has a market capitalization of C$140.28 million and generates C$791.59 million in revenue each year. Trilogy International Partners employs 1,883 workers across the globe.
What is Trilogy International Partners' official website?
How can I contact Trilogy International Partners?
Trilogy International Partners' mailing address is Bellevue Wa PO Box 1988, BELLEVUE, WA 98009-1988, United States. The specialty pharmaceutical company can be reached via phone at +1-425-4585900.
MarketBeat Community Rating for Trilogy International Partners (TSE TRL)
MarketBeat's community ratings are surveys of what our community members think about Trilogy International Partners and other stocks. Vote "Outperform" if you believe TRL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TRL will underperform the S&P 500 over the long term. You may vote once every thirty days.
